ZNTL logo

Zentalis Pharmaceuticals, Inc.

ZNTL
Healthcare|Biotechnology|US
$1.72
+0.01 (+0.58%)
Tangible Book / Share
$2.04
Cash / Share
$2.49
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Aug 14, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (4)

Dec 2026
Est. completion
P2High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825n=310
Jan 2027
Est. completion
P2Uterine Serous Carcinoma
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT06369155n=25
May 2028
Est. completion
P3Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500n=420
Jun 2028
Est. completion
P1Solid Tumor
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447n=172

Recent Press Releases

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 3, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Oct 23, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Oct 18, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Sep 2, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 17, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Aug 13, 2026 · GlobeNewsWire
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Aug 13, 2026 · GlobeNewsWire

SEC Filings (71)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 19, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026424B5Offering prospectusDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2026424B5Offering prospectusDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
May 27, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 27, 20268-KMaterial eventDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 17, 20268-KMaterial eventDocumentIndex
Apr 9, 20268-KMaterial eventDocumentIndex
Mar 26, 202610-KAnnual reportDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 9, 20268-KMaterial eventDocumentIndex
Jan 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 2, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Dec 30, 2025SC 13GPassive 5%+ stakeDocumentIndex
Dec 15, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Dec 15, 20258-KMaterial eventDocumentIndex
Nov 12, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Oct 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 26, 20258-KMaterial eventDocumentIndex
Aug 6, 202510-QQuarterly reportDocumentIndex
Aug 6, 20258-KMaterial eventDocumentIndex
Jul 16, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jun 18, 20258-KMaterial eventDocumentIndex
Jun 2, 20258-KMaterial eventDocumentIndex